315 related articles for article (PubMed ID: 26281139)
21. Impact of pretransplant donor-specific antibodies on kidney allograft recipients with negative flow cytometry cross-matches.
Kwon H; Kim YH; Choi JY; Shin S; Jung JH; Park SK; Han DJ
Clin Transplant; 2018 Jun; 32(6):e13266. PubMed ID: 29676812
[TBL] [Abstract][Full Text] [Related]
22. Incidences of preformed and de novo donor-specific HLA antibodies and their clinicohistological correlates in the early course of kidney transplantation.
Huang Y; Ramon D; Luan FL; Sung R; Samaniego M
Clin Transpl; 2012; ():247-56. PubMed ID: 23721029
[TBL] [Abstract][Full Text] [Related]
23. Impact of Low-Level Donor-Specific Anti-HLA Antibody on Posttransplant Clinical Outcomes in Kidney Transplant Recipients.
Lee H; Lee H; Eum SH; Ko EJ; Min JW; Oh EJ; Yang CW; Chung BH
Ann Lab Med; 2023 Jul; 43(4):364-374. PubMed ID: 36843405
[TBL] [Abstract][Full Text] [Related]
24. Early Intervention in Living Kidney Transplantation Based on Dynamic Monitoring of Donor Specific Antibodies.
Chen Y; Li LY; Lou XY; Wang H; Zhang L; Zhu YH
Clin Transpl; 2014; ():205-8. PubMed ID: 26281146
[TBL] [Abstract][Full Text] [Related]
25. Prevalence and impact of HLA and MICA allele mismatching on donor-specific antibodies induction in kidney transplant rejection.
Romphruk AV; Simtong P; Suntornnipat J; Sudwilai Y; Cheunta S; Chan-On C; Leelayuwat C
Nephrology (Carlton); 2021 Oct; 26(10):833-841. PubMed ID: 34197005
[TBL] [Abstract][Full Text] [Related]
26. Living donor kidney transplantation in patients with donor-specific HLA antibodies enabled by anti-CD20 therapy and peritransplant apheresis.
Klein K; Süsal C; Schäfer SM; Becker LE; Beimler J; Schwenger V; Zeier M; Schemmer P; Macher-Goeppinger S; Scherer S; Opelz G; Morath C
Atheroscler Suppl; 2013 Jan; 14(1):199-202. PubMed ID: 23357165
[TBL] [Abstract][Full Text] [Related]
27. Graft immunologic events in deceased donor kidney transplant recipients with preformed HLA-donor specific antibodies.
Ixtlapale-Carmona X; Arvizu A; De-Santiago A; González-Tableros N; López M; Castelán N; Marino LA; Uribe-Uribe NO; Contreras AG; Vilatobá M; Morales-Buenrostro LE; Alberú J
Transpl Immunol; 2018 Feb; 46():8-13. PubMed ID: 28974434
[TBL] [Abstract][Full Text] [Related]
28. Transplanting Sensitized Kidney Transplant Patients With Equivalent Outcomes Utilizing Stringent HLA Crossmatching.
Rohan VS; Taber DJ; Moussa O; Pilch NA; Denmark S; Meadows HB; McGillicuddy JW; Chavin KD; Baliga PK; Bratton CF
Exp Clin Transplant; 2017 Feb; 15(1):47-55. PubMed ID: 27267614
[TBL] [Abstract][Full Text] [Related]
29. Long-term post transplant alloantibody monitoring: a single center experience.
Ntokou IS; Boletis JN; Apostolaki M; Vrani V; Zavos G; Kostakis A; Iniotaki A
Clin Transpl; 2011; ():341-50. PubMed ID: 22755429
[TBL] [Abstract][Full Text] [Related]
30. Development of de novo HLA donor specific antibodies (HLA-DSA), HLA antibodies (HLA-Ab) and allograft rejection post blood transfusion in kidney transplant recipients.
Jalalonmuhali M; Carroll RP; Tsiopelas E; Clayton P; Coates PT
Hum Immunol; 2020 Jul; 81(7):323-329. PubMed ID: 32327243
[TBL] [Abstract][Full Text] [Related]
31. Donor-specific HLA antibodies: risk factors and outcomes after kidney transplantation.
Kanter Berga J; Pallardo Mateu LM; Beltran Catalan S; Puig Alcaraz N; Sancho Calabuig A; Gavela Martinez E; Avila Bernabeu A; Crespo Albiach J
Transplant Proc; 2011; 43(6):2154-6. PubMed ID: 21839219
[TBL] [Abstract][Full Text] [Related]
32. The Role of HLA Antibodies in HLA Mismatched Allogeneic Hematopoietic Stem Cell Transplantation.
Zhang X; Wang J; Zhou Z; Zhang Y; Liu H; Tong C; Yu C; Lu Y; Zhao Y; Xiong M; Zhou JR; Juan S; Liu DY; Wei Z; Zhang J; Wu T; Lu DP
Clin Transpl; 2014; ():245-50. PubMed ID: 26281152
[TBL] [Abstract][Full Text] [Related]
33. Characteristics of Circulating Donor Human Leukocyte Antigen-specific Immunoglobulin G Antibodies Predictive of Acute Antibody-mediated Rejection and Kidney Allograft Failure.
Kannabhiran D; Lee J; Schwartz JE; Friedlander R; Aull M; Muthukumar T; Campbell S; Epstein D; Seshan SV; Kapur S; Sharma VK; Suthanthiran M; Dadhania D
Transplantation; 2015 Jun; 99(6):1156-64. PubMed ID: 25629531
[TBL] [Abstract][Full Text] [Related]
34. Donor-specific HLA alloantibodies: Impact on cardiac allograft vasculopathy, rejection, and survival after pediatric heart transplantation.
Tran A; Fixler D; Huang R; Meza T; Lacelle C; Das BB
J Heart Lung Transplant; 2016 Jan; 35(1):87-91. PubMed ID: 26422083
[TBL] [Abstract][Full Text] [Related]
35. Impact of HLA antibodies on graft survival in long-term renal recipients with functional grafts.
Zeng Y; Liu Z; Liu Y; Fan Y; Guo Y; Qiu J
Urol Int; 2014; 92(3):328-33. PubMed ID: 24480999
[TBL] [Abstract][Full Text] [Related]
36. Deceased donor kidney transplantation across donor-specific antibody barriers: predictors of antibody-mediated rejection.
Schwaiger E; Eskandary F; Kozakowski N; Bond G; Kikić Ž; Yoo D; Rasoul-Rockenschaub S; Oberbauer R; Böhmig GA
Nephrol Dial Transplant; 2016 Aug; 31(8):1342-51. PubMed ID: 27190362
[TBL] [Abstract][Full Text] [Related]
37. Impact of alloantibody strength in crossmatch negative DSA positive kidney transplantation.
Wu P; Jin J; Everly MJ; Lin C; Terasaki PI; Chen J
Clin Biochem; 2013 Oct; 46(15):1389-93. PubMed ID: 23726814
[TBL] [Abstract][Full Text] [Related]
38. Does a Useful Test Exist to Properly Evaluate the Pathogenicity of Donor-specific Antibodies? Lessons From a Comprehensive Analysis in a Well-studied Single-center Kidney Transplant Cohort.
Gautier Vargas G; Olagne J; Parissiadis A; Joly M; Cognard N; Perrin P; Froelich N; Guntz P; Gachet C; Moulin B; Caillard S
Transplantation; 2020 Oct; 104(10):2148-2157. PubMed ID: 31895344
[TBL] [Abstract][Full Text] [Related]
39. Kidney Transplant With Low Levels of DSA or Low Positive B-Flow Crossmatch: An Underappreciated Option for Highly Sensitized Transplant Candidates.
Schinstock CA; Gandhi M; Cheungpasitporn W; Mitema D; Prieto M; Dean P; Cornell L; Cosio F; Stegall M
Transplantation; 2017 Oct; 101(10):2429-2439. PubMed ID: 28009780
[TBL] [Abstract][Full Text] [Related]
40. Pretransplant angiotensin II type 1-receptor antibodies are a risk factor for earlier detection of de novo HLA donor-specific antibodies.
Cuevas E; Arreola-Guerra JM; Hernández-Méndez EA; Salcedo I; Castelán N; Uribe-Uribe NO; Vilatobá M; Contreras-Saldívar AG; Sánchez-Cedillo AI; Ramírez JB; de Rungs D; Granados J; Morales-Buenrostro LE; Alberú J
Nephrol Dial Transplant; 2016 Oct; 31(10):1738-45. PubMed ID: 27220757
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
